Haem, 6
Haemoglobin, 4, 8, 10
Haemoproteins, 6
Haworth convention, 12
Heroin, 38
Heparin, 19
Histamine, 61
Histidine, 2
Histone, 10
Hydrophilic nature, 3, 50
Hydrophobic nature, 3, 50
8-Hydroxy-7-iodo-5-quinolinsulphonoic
acid, 69Hydroxymethylphenoxy resin, 117
R and S-Ibuprofens, 182
Imidazoles, 133–134
Imipramine, 188
Indacrinones, 61, 211
Insulin, 4, 7, 10
Interferons, 157
Intracellular fluid, 131, 245
Intercalating agents, 147
Ion channels, 132, 245, 247
Ionophores, 135–136
Ipronazid, 185
Isoleucine, 2
Isoelectric points (pIvalues)
amino acids, 3
proteins, 8, 9, 10Isoniazid, 185
Isoprenaline, 144
Isoprene, 23
Isosteres, 77
a-Keratins, 4
R-Ketamine, 54
S-Ketamine, 54
Kidney (seeElimination)
Lactic acid, 65
Lactose, 17
b-lactamase, 136
Lanosterol, 134
Lecithins, 25
Legistration, 177
Leucine, 2
Levodopa, 190
Ligand, 41, 109
Lignocaine, 52, 169, 185, 187, 194, 195
Limonene, 24
Linoleic acid, 20
Linolenic, 20
Lipids, 20
Lipophilicity, 78, 79–81
Lipopolysaccharides, 243
Lipoproteins, 6
Liver (seeElimination)
Lysine, 2
Lysozyme, 10Maltose, 17
Mannose, 14
Marketing authorisation, (SeeDrug
development)
Melphalan, 153
Menthol, 24
Mephenesin, 69
Mepivacaine, 168
6-Mercaptopurine, 77, 148, 149
Metabolism, 51
age and, 183
disease and, 183
drug design and, 193
environmental factors, 184
fats, 21
first pass metabolism, (See
Pharmacokinetics)
foetus and, 183
genetics and, 183
glucose, 4
hydroxylation, 76
pharmacokinetics, 234
lignocaine, 52
metabolite concentration, 193
metabolites, 51, 181
neonates and, 183
polysaccharides, 18
rate of, 73
secondary pharmaceutical implications, 184
sex and, 183
sites of action, 184
species, 184
stereochemistry of, 181–182
structural modifications, effect of, 194
Met-enkephalin, 7
Methionine, 2, 124
Methotrexate, 148, 149
5-Methylcytosine, 154
R- and S-Methyldopa, 54280 INDEX